Vivos Inc.'s Board of Directors granted authorization to form a wholly owned corporate subsidiary in India, with the name Vivos Scientific India LLP filed. This move signifies Vivos's long-term commitment to doing business in India and supports its strategic plan for international expansion. The company is completing the remaining steps to obtain formal approvals from the Indian government.
This new entity will support Vivos's long-term plan of establishing its first international manufacturing center for both RadioGel and IsoPet. It will also facilitate the expansion of developmental animal testing and the commercial treatment of humans and animals in India. India is considered an important region, especially after the initiation of the first human trials there in December 2024.
Vivos is actively pursuing Drug Controller General of India (DCGI) approval for additional expanded human trials in India. The company stated that its India trials are supportive of its Investigational Device Exemption (IDE) process with the FDA. The formal protocol for the next phase of human trials in India will include immediate post-treatment PET full-body scans to further validate RadioGel’s safety profile, based on feedback from the FDA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.